Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Investor Day (June 2024)

122 slides from Fresenius SE & Co. KGaA's investor day presentation, Jun 5, 2024

  1. Slide 1: Capital Markets Day 2024 – Fresenius Helios

    Capital Markets Day 2024 Fresenius Helios London, June 5, 2024

  2. Slide 2: Notice on the use of photographs and video recordings

    Notice on the use of photographs and video recordings Visit the Fresenius During this event, photos and video recordings of participants Capital Markets Day will be made. Some photos and/or recordings may possibly be used for future publication and marketing purposes of Fresenius website! Group and

  3. Slide 3: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to a variety of factors, e.g., changes in business, economic, and compe

  4. Slide 4: Capital Markets Day 2024 Agenda

    Capital Markets Day 2024 June 5, 2024 AGENDA Welcome/Opening Remarks Markus Georgi | Head of Investor Relations 10:30 am - 10:35 am #FutureFresenius Michael Sen | CEO Fresenius 10:35 am - 11:00 am Our Care Provision Platform Robert Möller | CEO Fresenius Helios & Helios Germany 11:00 am - 11:25 am F

  5. Slide 5: Today's Presenters

    Today’s Presenters Michael Sen Chairman of the Management Board Fresenius Management SE Michael Sen became Chairman of the Management Board of Fresenius (equivalent to President and CEO) on October 1, 2022. He joined Fresenius in April 2021 as Chairman of the Management Board of Fresenius Kabi. Befo

  6. Slide 6: Today's Presenters

    Today’s Presenters Robert Möller Ralph Böttcher CEO Fresenius Helios CFO Fresenius Helios and Helios Germany Fresenius Helios Robert Möller joined the Management Board of Fresenius in September 2023 with Ralph Böttcher joined Fresenius Helios as Chief Financial Officer in September 2023, responsibil

  7. Slide 7: Today's Presenters

    Today’s Presenters Víctor Madera Núñez Juan Antonio Álvaro de la Parra Founder and CEO COO Quirónsalud Quirónsalud Víctor Madera Núñez has been Chief Executive Officer of Quirónsalud since Juan Antonio Álvaro de la Parra has been the Chief Operating Officer of Quirónsalud January 2023. since the beg

  8. Slide 8: Today's Presenters

    Today’s Presenters Dr. Olaf Kannt Medical Consultant Helios Germany Dr. Olaf Kannt joined Helios Germany in 2004. In his role as Medical Consultant to the Helios Germany Group Management Board, he is responsible for the company's medical strategy and for driving medical specialization through hospit

  9. Slide 9: #FutureFresenius

    #FutureFresenius Michael Sen, CEO Fresenius Helios CMD – June 5, 2024

  10. Slide 10: A stronger and simpler company

    A stronger and simpler company 2

  11. Slide 11: This is Fresenius

    This is Fresenius OUR MISSION We save and improve human lives with affordable, accessible and innovative healthcare products and highest quality in clinical care OUR VISION We are the trusted, market-leading healthcare company that unites cutting-edge technology and human care to shape next-level th

  12. Slide 12: Healthcare: Strong needs underpinning secular sector growth

    Ageing global population +40% to 1.4B people >60 years worldwide by 2030 1 Increasing healthcare spend Health expenditures rise to >10% of global GDP by 2030 2 Higher prevalence of chronic diseases 84% of 67M deaths globally in 2030 due to chronic diseases 3 Demand for health workforce Healthcare: 1

  13. Slide 13: Addressing the driving forces of tomorrow's healthcare

    Addressing the driving forces of tomorrow's healthcare Multi-faceted Integrated health equity therapies Securing broad access Enabling targeted and and affordable healthcare multimodal treatment options Human-to- AI-powered human care clinical decisions Executing end-to-end Supporting efficient, cli

  14. Slide 14: #FutureFresenius: RESET delivered, now focusing on REVITALIZE

    #FutureFresenius: RESET delivered, now focusing on REVITALIZE Strategic portfolio measures concluded OpCo top and bottom line improving Structural simplification Sharpen focus New management team established FY24 Group outlook raised with Q1 Accelerate performance 6

  15. Slide 15: Focus on Fresenius Kabi and Fresenius Helios

    Focus on Fresenius Kabi and Fresenius Helios Fresenius Kabi Fresenius Helios Pharma Biopharma Nutrition MedTech (Bio)Pharma platform MedTech platform Care provision platform 7

  16. Slide 16: Operating Companies set up for value-accretive growth

    Operating Companies set up for value-accretive growth F³ - Fresenius Financial Framework Strong balance across growth and EBIT margin 14 – 17% 10 – 12% stable cash flow Ambitions raised Organic revenue growth 4 – 7% 4 – 6% F³ framework ambitions geared for substantial earnings FY2023 organic growth

  17. Slide 17: Fresenius Kabi: Accelerating our growth, driving performance

    Fresenius Kabi: Accelerating our growth, driving performance See Kabi CMD 2023 for more details PHARMA NUTRITION MEDTECH BIOPHARMA Overview Hospital-sold generic IV Enteral and Parenteral Stationary drug delivery AIID4 & oncology biologic Drugs and Fluids Nutrition products and therapy devices drugs

  18. Slide 18: Fresenius Helios: Reliable, system-critical care provision assets

    Fresenius Helios: Reliable, system-critical care provision assets HELIOS GERMANY QUIRÓNSALUD #1 hospital provider #1 private hospital provider Leading hospital provider in Europe Key facts 89% share of cases with better 1st hospital group globally w/ JCI performance vs. market average accreditation

  19. Slide 19: Steady and consistent growth performance over many years

    Steady and consistent growth performance over many years Fresenius Helios Revenues1 In €B, organic CAGR in % ~6% ~4% 12.0 11.4 10.7 9.7 9.1 8.4 8.7 Track record of reliable, consecutive organic growth in both segments 2017 2018 2019 2020 2021 2022 2023 Helios Germany Quirónsalud Total revenue CAGR (

  20. Slide 20: Remarkable patient satisfaction, responsive to regulatory change

    Remarkable patient satisfaction, responsive to regulatory change Remarkable patient satisfaction1 Responsive to regulatory change ~96% 2013 Pauschalierendes Entgeltsystem Psychiatrie und Psychosomatik … (PEPP) >90% 2016 Krankenhaus- strukturgesetz (KHSG) Provider of choice for patients for Long hist

  21. Slide 21: Outstanding capabilities for a leading care provision platform

    Outstanding capabilities for a leading care provision platform Unique scale and Superior medical Top-notch digital breadth of service quality and patient care offering and agenda Patient-centric System-critical 13

  22. Slide 22: The future of care provision…

    The future of care provision… Next-generation AI & data capabilities Cutting-edge therapy core 14

  23. Slide 23: The future of care provision starting to unfold

    The future of care Capitalizing on proprietary provision starting ~700k case data sets in know-how and data assets DE with broad consent to unfold E2E digital patient Proprietary Casiopea journey database EHR/HIS solution Digital twin model for hospital energy 6M patient portal Pharma R&D users in S

  24. Slide 24: Our strategy for capital-efficient revenue and earnings growth

    Our strategy for capital-efficient revenue and earnings growth Extend care provision ORP platform network AI AI-powered Outpatient medical data engine Clinical network lab Next-gen care consulting Clustering Clustering && Digital-led digital & Leveraging specialization specialization AI to transform

  25. Slide 25: Skilled, focused, and committed management team

    Skilled, focused, and committed management team Today’s presenters Víctor Madera Núñez Founder and CEO, Quirónsalud • Driving the success of Quirónsalud (previously Robert Möller IDCsalud) since the late 1990s • Physician; deeply rooted in Spanish healthcare system CEO, Fresenius Helios and Helios G

  26. Slide 26: Consistent value creation based on strong fundamentals

    Consistent value creation based on strong fundamentals Leading hospital provider with long track record of reliable organic growth Market-leading network in stable and attractive markets Highest medical quality, delivered by passionate healthcare professionals Expanding platform with adjacent servic

  27. Slide 27: Our Care Provision Platform

    Our Care Provision Platform Robert Möller, CEO Fresenius Helios & Helios Germany Helios CMD – June 5, 2024

  28. Slide 28: Fresenius – Committed to Life

    = Fresenius COMMITTED TO LIFE

  29. Slide 29: Quirónsalud

    @quironsalud

  30. Slide 30: We are the leading hospital care provider in Germany and Spain

    We are the leading hospital care provider in Germany and Spain GERMANY SPAIN 80+ 57 #1 hospital provider #1 private hospital provider hospitals (~6% market share) (~12% market share1) hospitals Position 89% 1st Share of cases with better Hospital group globally to receive performance vs. market aver

  31. Slide 31: We are the #1 hospital provider in Europe

    We are the #1 hospital provider in Europe I System-critical networks in stable and attractive markets II Long-term track record of consistent, reliable growth III Superior medical quality and best-in-class innovation IV Clear value creation plan for capital-efficient revenue and earnings growth, and

  32. Slide 32: System-critical network in stable and attractive markets

    System-critical network in stable and attractive markets Key growth drivers Demographics (e.g., aging ~€120B1 Hybrid system with ~3-4% population, lifestyle changes) public health insurance Total hospital reimbursement CAGR '23-'27 market 2023 Growing health awareness and patient engagement #1Market

  33. Slide 33: Long-term track record of consistent, reliable growth

    Long-term track record of consistent, reliable growth Fresenius Helios Revenues1 In €B, organic CAGR in % ~6% Consistent organic ~4% 12.0 revenue growth 11.4 10.7 9.7 9.1 8.4 8.7 Both segments contributing strongly Continuous success in 2017 2018 2019 2020 2021 2022 2023 regulated environment Helios

  34. Slide 34: Our strategy for capital-efficient revenue and earnings growth

    Our strategy for capital-efficient revenue and earnings growth Extend care provision ORP platform network AI AI-powered Outpatient medical data engine Clinical network lab Next-gen care consulting Clustering Clustering && Digital-led digital & Leveraging specialization specialization AI to transform

  35. Slide 35: Focus on the foundation of our shared success

    Focus on the foundation of our shared success Medical quality Digital & data capabilities ESG Note: ORP = Occupational risk prevention, HC = Healthcare 27

  36. Slide 36: Superior medical outcomes set us apart

    Superior medical outcomes set us apart Strong brand and Specialization & Leading medical Earlier discharge due Better medical positioning medical excellence advancements to superior quality outcomes Medical Krefeld 60+ Uerdingen Clusters of 25 -1.5 89% Excellence3 Krefeld-Hüls NPS1 in 2023 Chief phy

  37. Slide 37: Delivering better care and better efficiency at the same time

    Delivering better care and better efficiency at the same time Project Hope Patient-centric oncology treatment approach -25% INTEGRATED CARE MODEL improves reduction in hospitalizations coordination and patient throughput through improved monitoring -80% DIGITALIZATION OF PROCESSES enhances treatment

  38. Slide 38: Digital tools and smart data solutions improve performance

    Digital tools and smart data solutions improve performance Our support robots help us every day in selected hospitals Patient choice – learn more on our market stands Treatment Medical outcome Virtuous cycle Proprietary digital tools AI-based diagnoses Medical data strategy Telemedical treatments Di

  39. Slide 39: Triple win from medical data strategy

    Triple win from medical data strategy PCT1 assessments reduced through smart pattern analysis Illustrative, for one patient 0.40 Increasing patient 400 convenience and comfort 0.35 Biomarker to discriminate PCT1 within blood [ng/ml] CRP within blood [mg/l] 0.30 viral/bacterial infections, 300 e.g.,

  40. Slide 40: Our ESG strategy serves our patients, our people, and the planet

    Our ESG strategy serves our patients, our people, and the planet Performance Sample initiatives PATIENTS Inpatient Quality 100% Achieving and promoting quality metrics1 target achievement Indicators ISO 9001 certification in >90% of Helios hospitals in status quo PEOPLE Employee Engagement >90% Fost

  41. Slide 41: Impactful ESG initiatives in place and stronger efforts ahead

    Impactful ESG initiatives in place and stronger efforts ahead AI-based predictive Efficient & sustainable maintenance building mgmt. Recycling pilot Panel installment Anesthetic gas Use of emission reduction photovoltaics of absorbed anesthetic panels installed >90% gases recycled in pilot 11K in Sp

  42. Slide 42: Strong benchmarking program in place for full rollout in Q3'24

    Strong benchmarking program in place for full rollout in Q3'24 Medical Benchmarking Nursing Compare process effectiveness program Services Improve nurses' involvement Digital Tele- Benchmark tech performance Change radiology Increase diagnostic accuracy management ESG Real Compare energy efficiency

  43. Slide 43: Our contribution to Fresenius Financial Framework

    Our contribution to Fresenius Financial Framework AMBITIONS RAISED FY 2024 2027 2027 Outlook Ambition Ambition FY 2023 Q1 2024 Previous New Actuals Actuals Revenue growth organic p.a. +5% +5% Low- to mid-single Mid-single digit +4-6% p.a. digit %-growth %-growth (Previous: +3-5%) EBIT margin 10.0% 1

  44. Slide 44: We leverage our #1 position to become even stronger

    We leverage our #1 position to become even stronger Stable and attractive markets Clustering & specialization Outpatient integration Track record of reliable growth Emergency care provision Leveraging digital & AI to transform HC Superior medical quality Physician value proposition Clear value creat

  45. Slide 45: Fresenius Helios Financials

    Fresenius Helios Financials Ralph Böttcher, CFO Fresenius Helios Helios CMD – June 5, 2024

  46. Slide 46: Fresenius – Committed to Life

    = Fresenius COMMITTED TO LIFE

  47. Slide 47: Driving performance within and beyond a strong core

    Driving performance within and beyond a strong core Performance, cost & efficiency, cash delivery Note: ORP = Occupational risk prevention, HC = Healthcare 39

  48. Slide 48: We are Europe's #1 hospital provider

    We are Europe's #1 hospital provider 2027 Ambition 01 We deliver reliable organic revenue and earnings growth, and solid cash conversion Revenue growth (organic) +4-6% p.a. 02 We provide top-quality care, while driving (Previous: +3-5%) operating leverage and efficiency EBIT margin (% of sales) 03 W

  49. Slide 49: Data-driven performance ecosystem to deliver results

    Data-driven performance ecosystem to deliver results Dashboard example Performance ecosystem Extensive data pool Joint steering Change management Best-practice sharing Providing ~38K ~26M data on our Total number Total number Performance Group benchmarking network of beds1 of admissions2 ecosystem 1

  50. Slide 50: On track to realize sustainable EBIT margin uplift

    On track to realize sustainable EBIT margin uplift EBIT margin development Revenues In % of sales, illustrative In €M, illustrative +4-6% 10-12% p.a. Margins stabilizing EBIT 11% after recent pressure margin 10% band +1pp uplift vs. 2023 2027 previous structural EBIT Compensation of margin band Earn

  51. Slide 51: Growing earnings with strong volume and productivity gains

    Growing earnings with strong volume and productivity gains Earnings (EBIT) growth: Overview of key contributors In €B, illustrative EBIT Organic volume Price growth Cost inflation Productivity uplift EBIT 2023 growth 2027 Generally stable case-mix dynamic Revenue growth €12.0B +4-6% organic revenue

  52. Slide 52: Admissions growth within existing infrastructure

    Admissions growth within existing infrastructure Bed utilization In %, illustrative Potential for admissions growth using current capacity Optimal corridor Continuous ALOS1 optimization further adding capacity 70% Current +15-20pp utilization utilization uplift 57% potential Talent & productivity me

  53. Slide 53: Transparent pricing frameworks drive predictable price increases

    Transparent pricing frameworks drive predictable price increases Public Pricing Germany Private Pricing Spain Reimbursement negotiations Central BBFW1 adjustments Public hospital Public health union insurance union Individual Individual private private health providers insurances Binding treatment p

  54. Slide 54: Managing costs and scale to maximize operational leverage

    Managing costs and scale to maximize operational leverage Cost mechanics Illustrative Revenues increase organically € within existing infrastructure Revenues EBIT EBIT margin expansion through cost management Total costs Fixed costs Fixed costs stability with stepwise increases Variable costs Variab

  55. Slide 55: Productivity pushes quality and adds to bottom-line

    Productivity pushes quality and adds to bottom-line ~€130M structural cost savings potential by 2025 Key levers underpinning cost savings potential In €M, illustrative Resource Operations Synergies 170 optimization excellence & other Reduction of Reduction of process Unification of key ~130 leasing

  56. Slide 56: Focus on a stronger and simpler Fresenius Helios

    Focus on a stronger and simpler Fresenius Helios Ongoing portfolio simplification Focus on true medical excellence and performance to strengthen care delivery Exited Healthcare Apps 2023 end of year Curalie GmbH Transaction Helios Fertility 2024 closed in Jan Eugin Group Active portfolio review for

  57. Slide 57: Investing into improving patient care and earnings quality

    Investing into improving patient care and earnings quality Modernization & State-of-the-art Innovation & Selected capacity maintenance equipment sustainability expansion in Spain E.g., digital twin at Helios E.g., 1st proton beam E.g., AI for colon cancer E.g., expansion ENDO-Clinic to automate canc

  58. Slide 58: Growth paced by steady Capex levels

    Growth paced by steady Capex levels Capex In €M, in % of sales Sustainable, healthy Capex levels at ~5% of sales 5.5% 5.2% 4.8% 4.7% Lower Capex in Germany 568 560 573 for existing infrastructure 541 Higher Capex in Spain for selected expansions 2020 2021 2022 2023 2024 2027 (Indication) 50

  59. Slide 59: Substantial NWC reduction

    Optimizing net working capital (NWC) will release cash Focusing on active receivables management in Germany and Spain Substantial NWC Managing catch-up effects in 2024, reduction i.e., collection of nursing budget receivables Continuing concrete activities to optimize overall NWC needs 51

  60. Slide 60: Strong cash flows and ROIC contribution

    Strong cash flows and ROIC contribution Cash Conversion Rate1 Return on Invested Capital (ROIC) Times In % 1.0 1.0 0.9 0.9 5.4 5.4 5.2 5.0 2020 2021 2022 2023 2024 2027 2020 2021 2022 2023 2024 2027 (Indication) (Indication) Strengthened KPI focus to more actively track Contribution to Fresenius amb

  61. Slide 61: Our contribution to Fresenius Financial Framework

    Our contribution to Fresenius Financial Framework AMBITIONS RAISED FY 2024 2027 AMBITIONS RAISED Outlook Ambition FY 2023 Q1 2024 Actuals Actuals Previous FY 2024 New 2027 2027 Outlook Ambition Ambition Revenue FY 2023 Q1 2024 Previous New growth Actuals Actuals organic p.a. +5% +5% Low- to mid-sing

  62. Slide 62: Driving performance in our core business

    Driving performance in our core business We are committed to life. We are leading in our markets, delivering leading quality, and leading patient care We are committed to progress. We continue improving, raising our ambitions, and ensuring targeted investments in performance We are committed to resu

  63. Slide 63: Focus on Core Operations: Helios Germany

    Focus on Core Operations: Helios Germany Robert Möller, CEO Fresenius Helios & Helios Germany | Olaf Kannt, Medical Consultant Helios Germany Helios CMD – June 5, 2024

  64. Slide 64: Fresenius – Committed to Life

    = Fresenius COMMITTED TO LIFE

  65. Slide 65: Spotlight on our strong Helios Germany business

    Spotlight on our strong Helios Germany business Clustering & specialization Outpatient integration Emergency care provision Note: ORP = Occupational risk prevention, HC = Healthcare 57

  66. Slide 66: Helios Germany at a glance

    Maximum care Helios Germany 6 hospitals at a glance Hospitals in Germany Specialized of Fresenius Helios 10+ clinics ~60% revenues in 2023 Focused care 20+ hospitals 45+ General care 5.5M hospitals Patient admissions2 260+ 230+ Outpatient centers (MVZs) Out-of-hospital facilities 96% ORP5 274 center

  67. Slide 67: Delivering consistent and stable performance

    Delivering consistent and stable performance Revenues 01 We operate in a stable and attractive market with steady growth YoY organic growth '22-23: 4% Q1 2024: +4% vs. PY +4-6% p.a.1 Revenues in €B 7.0 7.3 02 We are a system-critical hospital provider, treating patients Bar sizes indicative with sup

  68. Slide 68: Clear reimbursement mechanisms in our ~€120B target market

    Clear reimbursement mechanisms in our ~€120B target market DRG revenues1 Nursing budget Reimbursement via diagnosis-related groups At-cost nursing expenditures ~15% Methodology Number of cases ~€120B3 Non-DRG revenues ~55% hospital market ~20% Surcharges for privately paid add-ons in Germany 2023 Re

  69. Slide 69: We expect moderate and stable market growth

    We expect moderate and stable market growth German hospital provider market In €B Price increases from Covid-19 support reimbursement adjustments3 payments 3-4% 3-4% Mental health revenues 3.5% Non-DRG Demographics driving revenues number of cases Nursing budget1 Aging population increasing DRG case

  70. Slide 70: Clear leader among hospital providers in Germany

    Clear leader among hospital providers in Germany Illustrative Hospitals by funding structure Hospital market share – top 5 players No. of hospitals In %; based on total hospital market revenues -0.5% 1,942 1,893 ~6% 37% 40% 34% 32% 29% 28% 2017 2018 2019 2020 2021 2022 #2 #3 #4 #5 … Private Nonprofi

  71. Slide 71: Our broad services enable us to care for patients in all settings

    Our broad services enable us to care for patients in all settings Leading hospital provider … … offering the full range of system-critical hospital care Fatima, 26 Emergency cases ~3K per day Admission to ICU4 after severe polytrauma Ines, 31 Childbirths3 ~35K per annum Birth of her first child Juer

  72. Slide 72: Scale of our network supports best-in-class performance

    Scale of our network supports best-in-class performance Leading hospital provider, with … Medical quality & excellence Best-practice sharing and data-driven guideline setting +1-2pp ! Visit our market stands about Organic revenue AI colon cancer detection growth above market1 Leading Digital solutio

  73. Slide 73: Innovation and best medical outcomes at the heart of our DNA

    Innovation and best medical outcomes at the heart of our DNA Culture of best medical care Relevant certifications and equipment Leading specialized care ERAS1 centers in hospitals 6 out of 9 Germany Strong best-practice- sharing initiatives >135 DKG2-certified centers 89% Share of cases with Continu

  74. Slide 74: We have grown profitably in a highly regulated environment

    We have grown profitably in a highly regulated environment Helios Germany revenues1 & key regulatory changes In €B +1-2pp Care Personnel Organic revenue Hospital Strengthening Act growth above market2 Structuring Act New mental health reimbursement mechanism Continuous revenue growth in context of r

  75. Slide 75: We are well positioned for upcoming regulatory changes

    We are well positioned for upcoming regulatory changes Details follow Details follow Hospital Hospital Hybrid Hospital Future Act Transparency Act DRG Reform Krankenhaus-Zukunftsgesetz Krankenhaus-Transparenzg. Hybrid-DRG-Verordnung Krankenhausreform KHVVG1 Status & Came into effect Came into effect

  76. Slide 76: Hybrid DRG: Leveraging our strong outpatient network

    Details on regulation Hybrid DRG | Leveraging our strong outpatient network Hybrid DRG provides new options for ambulatory reimbursement Outpatient treatments in hospital infrastructure AOP catalogue1 Freeing up capacity Hospitals for complex cases Increase of procedures eligible for Integrated trea

  77. Slide 77: Hospital Reform: Playing to our core strengths

    Details on regulation Hospital Reform | Playing to our core strengths QUALITY CAPACITY Core reform Introduction of Introduction of elements service groups1 standby financing2 Scale and ability to react to changes Resulting • Unified national • Change to current DRG changes quality criteria reimburse

  78. Slide 78: Clearly defined value creation levers fuel our profitable growth

    Clearly defined value creation levers fuel our profitable growth Medical Patient Revenue Earnings quality experience growth (EBIT) Value creation levers enhancement improvement growth Detailed view on following pages Extend medical cluster & a specialization strategy b Further improve outpatient int

  79. Slide 79: Capital-efficient growth in patient and treatment volumes

    Capital-efficient growth in patient and treatment volumes Bed utilization across Helios hospitals In % of total capacity Capacity for growth with current ~3% total ALOS1 reduction utilization below pre-Covid-19 levels Optimal +15-20pp patient admission corridor capacity within existing infrastructur

  80. Slide 80: Medical cluster & specialization strategy

    a Medical cluster & Before cluster strategy specialization strategy Stand-alone hospitals with similar offerings Complex treatments bundled into Clusters of Excellence Medical quality Integrated care strategy key for specialization Patient exp. After cluster strategy Shared department Unified approa

  81. Slide 81: Specialization drives cluster quality and treatment volume today

    Specialization drives cluster quality and treatment volume today No. of Da Vinci robotic surgeries CAGR '20-'24 +2x Krefeld +44% Specialized surgeries No. of bariatric surgeries Uerdingen +77%1 Elective interventions Double volume growth rates vs. ~40 peers in 20 km radius2 No. of knee and hip endop

  82. Slide 82: Cluster expansion to realize greater value

    Cluster expansion to realize greater value Step 1 Step 2 Step 3 Today's starting point Early adoption Advanced consolidation Clusters of Excellence Krefeld- Uerdingen 5 of today's 25 15 of today's 25 5 of today's 25 clusters (~20%) clusters (~60%) clusters (~20%) 1 year timeframe 2-3 years timeframe

  83. Slide 83: Outpatient integration

    b Outpatient integration Helios MVZs External MVZs & practices specialty overlap with admissions from >90% nearest Helios hospital >500k external referrals Medical average distance to physicians perceive Helios quality ~12km next Helios hospital >80% better or similar to peers2 Patient exp. Improvin

  84. Slide 84: External partners trust us with their patients' health

    External partners trust us with their patients' health Superior 25% Reduced mortality medical quality of patients1 Why partners refer their Access and patient 325K Registered patient patients to experience portal users2 our network Highest patient 96% Patient satisfaction satisfaction rates rating3

  85. Slide 85: Emergency care provision

    c Emergency care provision Emergency care units Admission decision Capacity constraint, Manual decision Medical with increasing process and lack of quality Challenges emergency care transparency on in care admission gap current bottlenecks Patient exp. Revenue Lack of hospital beds causes emergency

  86. Slide 86: Our revised approach enables best emergency care provision

    Helios solutions Our revised approach enables best emergency care provision Emergency care units Admission decision Zero downtime: Full-time availability of "Belegungsrecht": ECU2 personnel enabled emergency units to fill free capacity on inpatient wards Internal dashboards: "Downtime" tracking Digi

  87. Slide 87: Significant growth potential in adjacent business segments

    Significant growth potential in adjacent business segments Occupational risk prevention Details follow ios Germany revenues of Hel gments1 4% nt se Highly fragmented market with high demand ~1 adjace in ORP Helios to leverage market tailwinds & Quirónsalud capabilities in ORP network Outpatient Outp

  88. Slide 88: Occupational risk prevention

    Details on ORP Strong basis for a thriving future in ORP >35% revenues Strong CAGR '19-'23 Successful market entry, leveraging revenue Quirónsalud expertise growth 19 20 21 22 23 Attractive Highly accretive double- EBIT digit margin contributor margins Solid Strong reputation attracting client Occup

  89. Slide 89: Consistent & stable value creation based on strong fundamentals

    Consistent & stable value creation based on strong fundamentals We operate in a stable and attractive market with steady growth We are a system-critical hospital provider, treating patients with superior medical quality We are prepared for regulatory changes, benefitting from strong positioning of o

  90. Slide 90: Focus on Core Operations: Quirónsalud

    Focus on Core Operations: Quirónsalud Víctor Madera, Founder & CEO Quirónsalud | Juan Antonio Álvaro de la Parra, COO Quirónsalud Helios CMD – June 5, 2024

  91. Slide 91: Fresenius – Committed to Life

    = Fresenius COMMITTED TO LIFE

  92. Slide 92: Spotlight on our leading Quirónsalud business

    Spotlight on our leading Quirónsalud business ORP network Outpatient Clinical network lab Leveraging digital & AI to transform HC Mental health Physician value proposition Selective network expansion … Note: ORP = Occupational risk prevention, HC = Healthcare 84

  93. Slide 93: Quirónsalud at a glance

    Quirónsalud at a Spain hospitals Colombia hospitals ORP centers glance 50 hospitals and 130 71 hospitals and 10 ~300 centers strengthening outpatient centers outpatient centers brand and patient outreach of Fresenius Helios ~40% revenues in 2023 Clients include: Hospitals ORP centers Share of Quirón

  94. Slide 94: Our people at the core of what we do

    Our people at the core of what we do ~50,000 employees ~16,000 mercantile1 physicians 73% of female workers with most contracts indefinite2 Track record of unifying cultures after ~50 acquisitions Certified Top Employer in Spain3 1. Self-employed doctors contracted by Quirónsalud to provide their se

  95. Slide 95: We deliver holistic care services targeted to each patient's needs

    We deliver holistic care services targeted to each patient's needs Preventative Post-treatment medicine Preparation care Consultation for treatment Diagnosis Treatment/ Long-term Pre-consultation surgery follow-up assessment ~20M patient admissions '23, leveraging precision and personalized medicine

  96. Slide 96: Value creation from strong fundamentals and leading capabilities

    Value creation from strong fundamentals and leading capabilities Revenues 01 We operate in a stable and attractive market with steady growth YoY organic growth '22-23: 8% Q1 2024: +7% vs. PY +4-6% p.a.1 Revenues in €B 4.3 4.7 Bar sizes indicative 02 We are the leading hospital provider with unmatche

  97. Slide 97: Spanish hospital provider system snapshot

    Spanish hospital provider system snapshot Why pay for private Public Full coverage Co-payment- ~80% (~€85B) insurance? for 100% of free, financed of total provider system population (48M) through taxes expenditures Shorter waiting times Direct access to specialist doctors Complementary Paid by ~20%

  98. Slide 98: Attractive market with steady and resilient growth expected

    Attractive market with steady and resilient growth expected Spanish private provider market In €B Aging population Before Covid-19, market growth ~5% p.a. Strong increase of public-private agreements during Covid-19 drove increased market growth 4-5% 4-5% 7.5% 7.5% Out-of-pocket Lifestyle changes Pu

  99. Slide 99: Uptake in private health insurance boosts market growth

    Uptake in private health insurance boosts market growth Number of people with private health insurance policy Public system waiting list for surgery No. of people (in M) No. of people (in M) ~4% 0.8 ~4% 0.6 0.4 2007 2009 2011 2013 2015 2017 2019 2021 2023 13.5 11.6 12.5 10.8 9.9 Surgery average wait

  100. Slide 100: Overcoming physician availability constraints as growth catalyst

    Overcoming physician availability constraints as growth catalyst Physicians' availability in Spain1 No. of Physicians (in K) Number of physicians to remain flat vs. expected demand increase of ~4-5% ~0% ~2% Shortage of physicians coupled with growing demand leading to increased waiting times 100 100

  101. Slide 101: Strong growth of Quirónsalud coupled with best-in-class margins

    Strong growth of Quirónsalud coupled with best-in-class margins Quirónsalud total revenues1 In €B 4.7 Other 3.9 4.3 segments2 ~+1pp 3.4 Organic rev. growth 3.2 2.9 with strong track 2.7 record above market3 Quirónsalud hospitals in Spain ~12% 2017 2018 2019 2020 2021 2022 2023 EBIT margin in 2023 1.

  102. Slide 102: We are the leading private hospital provider in Spain

    We are the leading private hospital provider in Spain #2 Asturias Cantabria Basque #1 3 Market share – top 5 players Galicia Country Based on revenues2 3 Navarre ~12% #1 #1 Castile Rioja and Leon Aragon Catalonia #1 12 8 1 #1 #1 Madrid Competitors Estremadura #1 4 #3 Balearic Is. 1 2 3 4 5 Castile-L

  103. Slide 103: We are also leading in ORP and Colombian hospital market

    We are also leading in ORP and Colombian hospital market ORP Colombia hospitals Market share – top 5 players Market share – top 5 players Based on revenues1 Based on revenues2 ~1.6x next player Nearly equal to 1st player 1 2 3 4 5 1 2 3 4 5 Competitors Competitor Competitors Leading the Spanish ORP

  104. Slide 104: 3 core pillars make Quirónsalud the top choice for patients

    3 core pillars make Quirónsalud the top choice for patients Best-in-class healthcare Highest healthcare quality Best-in-class patient professionals and hospitals and standards experience #1 private provider with leading 1st private group globally with JCI1 >90% patient satisfaction recognized presen

  105. Slide 105: Latest technology and equipment as key pillar of leading offering

    Latest technology and equipment as key pillar of leading offering 1st 3 Proton therapy center in Spain ROSA surgical robots 126 2 MRIs1 Mazor surgical robots 23 Linear accelerators, including 1 Gamma Knife 1 MRIgART 2 1 CyberKnife 8 76 Multi-slice CT scans Hybrid operating rooms 16 PET-CTs 13 11 SPE

  106. Slide 106: Extensive innovation and research at our core

    Extensive innovation and research at our core Clinical trials Research 1,355 Active clinical 658 Research trials projects 408 New clinical 274 Observational trials in 2023 studies Clinical trials Publications & in early stages patents 215 Clinical trials in 1,738 Publications early stages in 2023 3

  107. Slide 107: Strong learning and development opportunities

    Strong learning and development opportunities University Quirónsalud Training courses Rotational hospitals & Nursing University & programs programs residency seats schools ~30,000 +800,000 hours Network-wide 8 accredited Centers professionals of internal programs across university affiliated with tr

  108. Slide 108: Our network and capabilities form a base for next stage of growth

    Our network and capabilities form a base for next stage of growth Building the Developing Reshaping network capabilities healthcare 2015 2019 2020 2023 2024 … Our next stage of growth Establishing a network Developing top-tier Driving organic growth and with unmatched capabilities and shaping the tr

  109. Slide 109: Clearly defined value creation levers fuel our profitable growth

    Clearly defined value creation levers fuel our profitable growth Medical Patient Revenue Earnings quality experience growth (EBIT) Value creation levers enhancement improvement growth Detailed view on following pages Leveraging digital, data & AI to shape the a transformation of the healthcare secto

  110. Slide 110: Digital-led transformation provides benefits across the board

    a Leverage digital and AI to Digital-led transformation provides transform healthcare benefits across the board Patients Faster access to healthcare Medical Optimized and more quality personalized experience From activity- based to Patient process- and exp. 1 outcomes-based medicine, supported Quiró

  111. Slide 111: Proprietary digitalization and data tools driving transformation

    Proprietary digitalization and data tools driving transformation HIS1 – Casiopea Patient Portal Digital Hospital Proprietary HIS Casiopea, integrated Proprietary patient portal (web- & Proprietary digital hospital Functionalities with physicians, patients, app-based) for accessing medical complement

  112. Slide 112: Healthcare experience transformed across entire patient journey

    Healthcare experience transformed across entire patient journey Patient journey Before attendance During attendance After attendance From reactive to proactive From isolated acts to care From volume metrics to medicine pathways evaluating the real value for patients Consultation preparation, Standar

  113. Slide 113: Streamlined patient journeys increasing physician productivity

    Streamlined patient journeys increasing physician productivity Illustrative example 1: Consultation preparation Patient Waiting Request for Treatment From referral times diagnosis tests Surgery 1º CEX Boosting efficiency 800+ 2º CEX … across streamlined Patient Request for SOPs1 healthcare processes

  114. Slide 114: Impact documented and published in peer-reviewed papers

    Impact documented and published in peer-reviewed papers 106

  115. Slide 115: Quirónsalud is well positioned to address the physician shortage

    b Double down on physician Quirónsalud is well positioned to address value proposition the physician shortage • Extend network of accredited university Medical hospitals and nursing schools quality • Increase number of residency seats Develop in-house talent by 60-100 Differential value Patient • Fo

  116. Slide 116: Selective expansion plans will drive additional volume growth

    c Conduct selective Selective expansion plans will drive network expansion additional volume growth 2 recent openings 4 expansions/relocations planned between 2024 and 2026 Medical quality Selectively enhance or substitute existing facilities to ensure Selected delivery of best-in-class patient care

  117. Slide 117: New openings to strengthen our leading position and fuel growth

    New openings to strengthen our leading position and fuel growth Olympia – Madrid Zaragoza Greenfield opening – 2022 Expansion and relocation – 2024 Badajoz Badalona Expansion and relocation – 2026 Greenfield opening – 2023 Málaga/Marbella Valencia Expansion – 2023/24 Expansion and relocation – 2026

  118. Slide 118: Value creation from strong fundamentals and leading capabilities

    Value creation from strong fundamentals and leading capabilities We operate in a stable and attractive market with steady growth We are the leading hospital provider with unmatched capabilities, making us the top choice for patients We have a clearly defined value creation plan to achieve capital-ef

  119. Slide 119: Closing Remarks

    Closing Remarks Michael Sen, CEO Fresenius Helios CMD – June 5, 2024

  120. Slide 120: Our strategy for capital-efficient revenue and earnings growth

    Our strategy for capital-efficient revenue and earnings growth Extend care provision ORP platform network AI AI-powered Outpatient medical data engine Clinical network lab Next-gen care consulting Clustering Clustering && Digital-led digital & Leveraging specialization specialization AI to transform

  121. Slide 121: Consistent value creation based on strong fundamentals

    Consistent value creation based on strong fundamentals Leading hospital provider with long track record of reliable organic growth Market-leading network in stable and attractive markets Highest medical quality, delivered by passionate healthcare professionals Expanding platform with adjacent servic

  122. Slide 122: Fresenius – Committed to Life

    = Fresenius COMMITTED TO LIFE

Fresenius SE & Co. KGaA — Investor Day (June 2024) on 6ix